Nonalcoholic fatty liver disease was independently associated with an increased risk of ventricular arrhythmias in patients with type 2 diabetes (adjusted OR 3.01; 95% CI 1.26-7.17; P=0.013).
Observational (n=330)
Is nonalcoholic fatty liver disease associated with an increased risk of ventricular arrhythmias in patients with type 2 diabetes?
In patients with type 2 diabetes, the presence of NAFLD is independently associated with a significantly increased risk of prevalent ventricular arrhythmias.
Odds Ratio: 3.01 (95% CI 1.26–7.17)
Absolute Event Rate: 27.3% vs 9.8%
p-value: p=0.013
OBJECTIVE: Recent studies have suggested that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of heart rate-corrected QT interval prolongation and atrial fibrillation in patients with type 2 diabetes. Currently, no data exist regarding the relationship between NAFLD and ventricular arrhythmias in this patient population. RESEARCH DESIGN AND METHODS: We retrospectively analyzed the data of 330 outpatients with type 2 diabetes without preexisting atrial fibrillation, end-stage renal disease, or known liver diseases who had undergone 24-h Holter monitoring for clinical reasons between 2013 and 2015. Ventricular arrhythmias were defined as the presence of nonsustained ventricular tachycardia (VT), >30 premature ventricular complexes (PVCs) per hour, or both. NAFLD was diagnosed by ultrasonography. RESULTS: Compared with patients without NAFLD, those with NAFLD (n = 238, 72%) had a significantly higher prevalence of >30 PVCs/h (19.3% vs. 6.5%, P < 0.005), nonsustained VT (14.7% vs. 4.3%, P < 0.005), or both (27.3% vs. 9.8%, P < 0.001). NAFLD was associated with a 3.5-fold increased risk of ventricular arrhythmias (unadjusted odds ratio OR 3.47 95% CI 1.65-7.30, P < 0.001). This association remained significant even after adjusting for age, sex, BMI, smoking, hypertension, ischemic heart disease, valvular heart disease, chronic kidney disease, chronic obstructive pulmonary disease, serum γ-glutamyltransferase levels, medication use, and left ventricular ejection fraction (adjusted OR 3.01 95% CI 1.26-7.17, P = 0.013). CONCLUSIONS: This is the first observational study to show that NAFLD is independently associated with an increased risk of prevalent ventricular arrhythmias in patients with type 2 diabetes.
Mantovani et al. (Mon,) conducted a observational in Type 2 diabetes (n=330). Nonalcoholic fatty liver disease (NAFLD) vs. Patients without NAFLD was evaluated on Ventricular arrhythmias (nonsustained ventricular tachycardia, >30 premature ventricular complexes per hour, or both) (adjusted OR 3.01, 95% CI 1.26-7.17, p=0.013). Nonalcoholic fatty liver disease was independently associated with an increased risk of ventricular arrhythmias in patients with type 2 diabetes (adjusted OR 3.01; 95% CI 1.26-7.17; P=0.013).